BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bookstaver PB, Milgrom A. Stewarding the costly antibiotic: considerations for dalbavancin. Clin Infect Dis 2020:ciaa1730. [PMID: 33211844 DOI: 10.1093/cid/ciaa1730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Buzón-Martín L, Zollner-Schwetz I, Tobudic S, Cercenado E, Lora-Tamayo J. Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. Antibiotics (Basel) 2021;10:656. [PMID: 34072670 DOI: 10.3390/antibiotics10060656] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Gatti M, Andreoni M, Pea F, Viale P. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. Drug Des Devel Ther 2021;15:3349-78. [PMID: 34376971 DOI: 10.2147/DDDT.S313756] [Reference Citation Analysis]
3 Antosz K, Al-Hasan MN, Lu ZK, Tabor B, Justo JA, Milgrom A, Kohn J, Bookstaver PB. Clinical Utility and Cost Effectiveness of Long-Acting Lipoglycopeptides Used in Deep-Seated Infections among Patients with Social and Economic Barriers to Care. Pharmacy (Basel) 2021;10:1. [PMID: 35076601 DOI: 10.3390/pharmacy10010001] [Reference Citation Analysis]